Yang, Mingli

lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling

Lu, Y., Zhao, X., Liu, Q., Li, C., Graves-Deal, R., Cao, Z., Singh, B., Franklin, J. L., Wang, J., Hu, H., et al. (2017) · Nature Medicine

MicroRNA in disease regulationCancer-related molecular mechanisms research

Cited by 425

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 207

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

Schell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 42

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation

Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 27

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016) · BMC Medical Genomics

Colorectal Cancer Treatments and StudiesGene expression and cancer classification

Cited by 25

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 22

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC

Davis, T. B., Yang, M., Wang, H., Lee, C., Yeatman, T. J., & Pledger, W. J. (2019) · Oncotarget

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 11